TrialThe oncologist2023

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.

Juan Luis Gomez Marti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.